Recombinant Cynomolgus/Rhesus FGL2 His-tag Protein, CF

When Recombinant Human Fc gamma RIIB/C (CD32b/c) (1875-CD) is immobilized at 2 µg/mL (100 µL/well), Recombinant Cynomolgus Monkey/Rhesus Macaque FGL2 His-tag Protein (Catalog # 11193-FL) binds with an ED50 of 60.0-900 ng/mL.

• Reactivity: Pm-Cm, RM
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus/Rhesus FGL2 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Fc gamma RIIB/C (CD32b/c) (Catalog # 1875-CD) is immobilized at 2 µg/mL (100 µL/well), Recombinant Cynomolgus Monkey/Rhesus Macaque FGL2 His-tag (Catalog # 11193-FL) binds with an ED₅₀ of 60.0-900 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived FGL2 protein
  Asn24-Pro439, with a C-terminal 6-His tag
• Accession #: XP_005550475.1
• N-terminal Sequence: Asn24 and Asp32
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 49 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 54-78 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus/Rhesus FGL2 His-tag Protein, CF

• FGL2
• fibrinogen-like 2
• Fibrinogen-like protein 2
• Fibroleukin
• pT49T49
• T49

Background

FGL2 (fibrinogen-like protein 2), also called fibroleukin, is a 64-70 kDa secreted glycoprotein of the Fibrinogen-like superfamily. It has prothrombinase activity and also promotes T regulatory (Treg) activity (1-6). The human FGL2 gene encodes a 439 amino acid (aa) protein that contains a 23 aa signal sequence and a 416 aa mature sequence with a coiled-coil region and a fibronectin C-terminal homology domain or FRED (1, 2). A 260-280 kDa FGL2 complex is thought to be a tetramer formed by covalent disulfide linkage of dimers that are associated via coiled-coil interactions (2, 3). Mature cynomolgus monkey/rhesus macaque FGL2 shares 99.3% aa identity with human FGL2. FGL2 appears to have two modes of action. One mode involves its prothrombinase activity, which requires calcium and acidic phospholipids (4). This mode is thought to be active during hepatitis viral infections when FGL2, produced by macrophages in response to IFN-gamma, induces hepatic apoptosis and fibrin deposition (7). In addition, FGL2 produced by endothelial cells in response to TNF-alpha within cardiac xenografts or allografts promotes coagulation during acute vascular rejection (7-9). A second mode of action involves soluble (not phospholipid-associated) FGL2 and is independent of prothrombinase activity (2). Soluble FGL2 is required for Treg function, and directly suppresses DC, T, and B cell immune reactivity; consequently, some FGL2-deficent mice develop autoimmune glomerulonephritis (5, 6). In vitro, soluble FGL2 can skew T cell polarization toward Th2 and inhibit proliferation of stimulated T cells and maturation of DC (6). In pregnancy, fetal trophoblast cells secrete FGL2. The immune suppressive mode of FGL2 may prevent early fetal loss; however, the procoagulant mode is thought to mediate infection-triggered abortion (10). In the central nervous system (CNS), FGL2 was shown to be highly expressed in glioma stem cells and primary glioblastoma cells and may serve as a critical immune oncology target (11).

1. Koyama, T. et al. (1987) Proc. Natl. Acad. Sci. USA 84:1609.
2. Marazzi, S. et al. (1998) J. Immunol. 161:138.
3. Olson, G. E. et al. (2004) J. Biol. Chem. 279:51266.
4. Chan, C. W. Y. et al. (2002) J. Immunol. 168:5170.
5. Shalev, I. et al. (2008) J. Immunol. 180:249.
6. Chan, C. W. Y. et al. (2003) J. Immunol. 170:4036.
7. Liu, M. et al. (2006) J. Immunol. 176:7028.
8. Mendicino, M. et al. (2005) Circulation 112:248.
9. Ning, Q. et al. (2005) J. Immunol. 174:7403.
10. Clark, D. A. et al. (2004) Mol. Hum. Reprod. 10:99.
11. Yan J. et al. (2019) Nat Commun. 10:448.

Bioinformatics

• Uniprot:
  • XP_005550475.1()